Straits Times Index
3,309.21 -12.87 (-0.39%) S&P 500
5,360.79 +13.80 (+0.26%) Dow
38,868.04 +69.05 (+0.18%) Nasdaq
17,192.53 +59.40 (+0.35%) Bitcoin USD
66,843.98 -2,594.10 (-3.74%) CMC Crypto 200
1,390.41 -51.23 (-3.55%)
SAGE Jan 2026 20.000 call
| Previous close | 2.2000 |
| Open | 1.6800 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 20.00 |
| Expiry date | 2026-01-16 |
| Day's range | 1.6000 - 2.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
Business WireSage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
CAMBRIDGE, Mass., June 11, 2024--Sage Therapeutics announced today topline results from the Phase 2 SURVEYOR Study. The study met its primary endpoint demonstrating a statistically significant difference as measured by the HD-Cognitive Assessment Battery (HD-CAB) composite score at baseline between healthy participants and participants with Huntington’s Disease (HD) prior to any treatment with dalzanemdor (SAGE-718) or placebo.
Business WireSage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
CAMBRIDGE, Mass., June 05, 2024--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 2:00 p.m. ET in Miami, FL.
- Investing.com
Baird predicts steady growth for SAGE Therapeutics at $15 target
Investing.com - Baird Equity Research has initiated coverage of SAGE Therapeutics Inc (NASDAQ:SAGE), assigning it a neutral rating with a price target of $15.
